Cargando…

A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice

Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Erica G., Toth, Kelsey A., Risma, Samuel I., Kolicheski, Ana, Saucier, Nermina, Berríos, Rafael J. Feliciano, Greenberg, Zev J., Leiding, Jennifer W., Bleesing, Jack J., Thatayatikom, Akaluck, Schuettpelz, Laura G., Edwards, John R., Vogel, Tiphanie P., Cooper, Megan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675480/
https://www.ncbi.nlm.nih.gov/pubmed/36136607
http://dx.doi.org/10.1172/jci.insight.162695
_version_ 1784833383222738944
author Schmitt, Erica G.
Toth, Kelsey A.
Risma, Samuel I.
Kolicheski, Ana
Saucier, Nermina
Berríos, Rafael J. Feliciano
Greenberg, Zev J.
Leiding, Jennifer W.
Bleesing, Jack J.
Thatayatikom, Akaluck
Schuettpelz, Laura G.
Edwards, John R.
Vogel, Tiphanie P.
Cooper, Megan A.
author_facet Schmitt, Erica G.
Toth, Kelsey A.
Risma, Samuel I.
Kolicheski, Ana
Saucier, Nermina
Berríos, Rafael J. Feliciano
Greenberg, Zev J.
Leiding, Jennifer W.
Bleesing, Jack J.
Thatayatikom, Akaluck
Schuettpelz, Laura G.
Edwards, John R.
Vogel, Tiphanie P.
Cooper, Megan A.
author_sort Schmitt, Erica G.
collection PubMed
description Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3(+) Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4(+) Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8(+) T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD.
format Online
Article
Text
id pubmed-9675480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-96754802022-11-21 A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice Schmitt, Erica G. Toth, Kelsey A. Risma, Samuel I. Kolicheski, Ana Saucier, Nermina Berríos, Rafael J. Feliciano Greenberg, Zev J. Leiding, Jennifer W. Bleesing, Jack J. Thatayatikom, Akaluck Schuettpelz, Laura G. Edwards, John R. Vogel, Tiphanie P. Cooper, Megan A. JCI Insight Research Article Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3(+) Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4(+) Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8(+) T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD. American Society for Clinical Investigation 2022-11-08 /pmc/articles/PMC9675480/ /pubmed/36136607 http://dx.doi.org/10.1172/jci.insight.162695 Text en © 2022 Schmitt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Schmitt, Erica G.
Toth, Kelsey A.
Risma, Samuel I.
Kolicheski, Ana
Saucier, Nermina
Berríos, Rafael J. Feliciano
Greenberg, Zev J.
Leiding, Jennifer W.
Bleesing, Jack J.
Thatayatikom, Akaluck
Schuettpelz, Laura G.
Edwards, John R.
Vogel, Tiphanie P.
Cooper, Megan A.
A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title_full A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title_fullStr A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title_full_unstemmed A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title_short A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
title_sort human stat3 gain-of-function variant confers t cell dysregulation without predominant treg dysfunction in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675480/
https://www.ncbi.nlm.nih.gov/pubmed/36136607
http://dx.doi.org/10.1172/jci.insight.162695
work_keys_str_mv AT schmittericag ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT tothkelseya ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT rismasamueli ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT kolicheskiana ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT sauciernermina ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT berriosrafaeljfeliciano ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT greenbergzevj ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT leidingjenniferw ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT bleesingjackj ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT thatayatikomakaluck ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT schuettpelzlaurag ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT edwardsjohnr ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT vogeltiphaniep ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT coopermegana ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT schmittericag humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT tothkelseya humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT rismasamueli humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT kolicheskiana humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT sauciernermina humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT berriosrafaeljfeliciano humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT greenbergzevj humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT leidingjenniferw humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT bleesingjackj humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT thatayatikomakaluck humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT schuettpelzlaurag humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT edwardsjohnr humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT vogeltiphaniep humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice
AT coopermegana humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice